| Accession |
PRJCA022414 |
| Title |
A non-comparative, open, Phase II study of ruxolitinib in polycythemia vera subjects who are resistant to or intolerant of hydroxyurea or Interferon alpha |
| Relevance |
Medical |
| Data types |
Targeted Locus (Loci)
Variation
|
| Organisms |
Homo sapiens
|
| Description |
The emerging efficacy and safety profile for ruxolitinib supports further studies in Chinese PV subjects who demonstrate resistance or intolerance to HU or IFN-α therapy. The purpose of this trial is to demonstrate clinically meaningful responses in PV subjects receiving ruxolitinib |
| Sample scope |
Multiisolate |
| Release date |
2023-12-27 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| Ministry of Science and Technology of the People's Republic of China (MOST)
|
|
CINC424BCN01T
|
|
|
|
| Submitter |
yating
liu (liuyating@ihcams.ac.cn)
|
| Organization |
tianjin |
| Submission date |
2023-12-27 |
